Read this company snapshot
Daily valuation snapshot
Pharvaris N.V. Ordinary Shares: source evidence dated 2026-10-11.
- Daily close (USD)
- Not reported
- Market capitalization (USD)
- Not reported
- Price / earnings (TTM)
- Not reported
- Price / book
- Not reported
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research PHVS in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research PHVS in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Daily valuation snapshot
See the complete daily valuation snapshot
Use the company overview and research links to continue. This response has no daily market snapshot values to display.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | Not reported |
| Market capitalization (USD) | Not reported |
| Price / earnings (TTM) | Not reported |
| Price / book | Not reported |
No matching rows. Clear the filter to see all records.
Read PHVS's valuation metrics
Company size
Market capitalization measures the market value of the company's equity. Read it alongside revenue, earnings and debt when comparing company size.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
Price-to-book compares market equity value with recorded book equity. Intangible assets, profitability and the company's business affect how useful the comparison is.
Research Pharvaris N.V. Ordinary Shares with Aurora
Use the snapshot above to ask a specific question about PHVS. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow PHVS's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.